Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Commentaries on Cutting Edge Science

Keep PNUTS in Your Heart

Francesco S. Loffredo, James R. Pancoast, Richard T. Lee
Download PDF
https://doi.org/10.1161/CIRCRESAHA.113.301933
Circulation Research. 2013;113:97-99
Originally published July 5, 2013
Francesco S. Loffredo
From the Harvard Stem Cell Institute, The Brigham Regenerative Medicine Center and The Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James R. Pancoast
From the Harvard Stem Cell Institute, The Brigham Regenerative Medicine Center and The Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard T. Lee
From the Harvard Stem Cell Institute, The Brigham Regenerative Medicine Center and The Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • MicroRNA-34a Regulates Cardiac Ageing and FunctionBoon et alNature. 2013;495:107–110.
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

MicroRNA-34a Regulates Cardiac Ageing and Function
Boon et al
Nature. 2013;495:107–110.

Aging is a major factor in many cardiovascular diseases. The molecular factors that regulate age-related changes in cardiac physiology and contribute to the increased cardiovascular risk in the elderly are not fully understood. A study recently published in Nature suggests a specific role for microRNAs (miRNAs) in regulating cardiac aging and function, challenging the concept that aging is an inevitable process in the heart.

Aging is an evolutionarily conserved yet poorly understood process that leads to deterioration of many physiological functions during the lifespan of an organism.1 Aging increases the risk of cardiovascular diseases and leads to worse clinical outcomes.2 Elderly patients have an increased risk of acute myocardial infarction (MI) and an increase in both in-hospital and postdischarge mortality.3 The capability of the adult mammalian heart to replenish its cardiomyocyte pool both during physiological aging and in response to injury has now been definitively established.4,5 However, cardiomyocyte refreshment occurs at a low rate (≈1%/y) even in youth and seems to slow with advancing age.4 Recent evidence suggests that some of the aging hallmarks, like age-related cardiac hypertrophy, are regulated by hormones and can be reversed.6 The molecular mechanisms that regulate cardiac aging are complex and not yet completely understood.

In the March 31, 2013, issue of Nature, Boon et al7 describe a new molecular pathway that regulates cardiac aging. Using a microarray approach, the authors identified several miRNAs, including miR-34a, that change with age. miR-34a increases with age and acts as a regulator of telomere shortening, DNA damage, and apoptosis in cardiomyocytes, whereas its inhibition improves functional recovery after acute MI (Figure). miRNAs are endogenous noncoding single-stranded small regulatory RNA molecules, ≈22 nucleotides in length, and these RNAs play an important role in the regulation of gene expression.8 miRNAs can silence the expression of multiple genes with an average miRNA having >100 targets,9 and thus miRNAs have the potential to regulate at least a third of the human genes.10 miRNAs participate in many cardiovascular biological processes by regulating heart development, cardiac regeneration, and aging and by modulating gene.11–13

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Schematic of miR-34a interaction and effects on the heart. Boon et al7 describe miR-34a, a microRNA (miRNA) that is upregulated with age and after myocardial infarction. Increases in miR-34a result in reduced expression of phosphatase 1 nuclear–targeting subunit (PNUTS). miRNA inhibition or genetic deletion of miR-34a leads to upregulation of PNUTS translating to reduced apoptosis, DNA damage response, and an improvement in cardiac function after myocardial infarction.

In this new study, Boon et al7 compared groups of young and old mice and unsurprisingly found the hearts of aged mice exhibited increased fibrosis, cardiac hypertrophy, shorter telomeres, and increased cardiomyocyte apoptosis. To identify factors that are dysregulated with age and can contribute to the development of the aging cardiac phenotype, the authors performed miRNA microarray profiling. They identified miRNAs that are differentially expressed in the 2 experimental populations, and they discovered that the miRNA-34 family is upregulated in an age-dependent manner. This miRNA family contains 3 members: miR-34a, miR-34b, and miR-34c, and the authors showed that miR-34a expression is upregulated in aging hearts and specifically in cardiomyocytes. miR-34a plays a crucial role in p53-induced cell cycle arrest, cell senescence, and apoptosis14; and miR-34a is also known to induce apoptosis in cancer cell lines.15 The authors also showed that miR-34a expression increases in human hearts with age, suggesting that a similar pathway might regulate cardiac aging in humans.

Inhibition of miR-34a in rat neonatal cardiomyocytes reduced H2O2-induced apoptosis, and overexpression of miR-34a increased apoptosis, suggesting a specific role of miR-34a in regulation of apoptosis in cardiomyocytes. In line with this intriguing in vitro finding, Boon et al7 showed that by inhibiting miR-34a via administration of an antisense antagomir in vivo, cardiomyocyte apoptosis in aging mice was significantly reduced after 1 week of treatment. To further study the impact of miR-34a on cardiac function, the authors developed miR-34a knockout (miR-34a−/−) mice. The miR-34a−/− mice line showed no increase in mortality or specific phenotype and will be published by the authors in a follow-up article. Interestingly, aged miR-34a−/− mice have reduced cardiac hypertrophy compared with miR-34a+/+ mice. The effect of miR-34a was further confirmed by showing that pharmacological inhibition of miR-34a by locked nucleic acid–based anti-miRs can rescue the expected reduction in cardiac contractile function in the Ku80−/− genetic model for accelerated aging.16

The finding that miR-34a inhibition reduces apoptosis and preserves cardiac function raises the hypothesis that miR-34a could be involved in the pathophysiology of MI, where apoptosis and fibrosis are important hallmarks. The authors found that miR-34a is indeed upregulated in border zone after MI in mice. Furthermore, pharmacological inhibition of miR-34a for 2 weeks after MI results in improved cardiac contractile function, reduced cell death, and a reduction in scar area. It is not yet clear whether this effect is a result of regulation of fibrosis, apoptosis, or both.

miR-34a targets the class III histone deacetylase SIRT1 in endothelial and endothelial progenitor cells13 and induces apoptosis in cancer cells17; SIRT1 is essential for neovascularization after ischemia18 and its suppression by miR-34a negatively affects endothelial cells function.13 In line with this, the authors observed that inhibition of miR-34a resulted in a reduction in rates of cell death in noncardiomyocytes after infarction. In particular, they observed increased neovascularization in mice that were treated with the inhibitors, suggesting that the overall positive effect on cardiac function after infarction can be multifactorial, including inducing resistance to programmed cell death and improving regional perfusion.

Study of the mechanistic role of miR-34a in regulating cardiac function as a function of age unveiled a novel and SIRT1-independent pathway that underlies senescence in cardiomyocytes. Using multiple miRNA prediction tools, Boon et al7 were able to narrow the pool of potential targets to a single gene, Ppp1r10 (also known as protein phosphatase 1 nuclear–targeting subunit [PNUTS]) that was predicted as a target of miR-34a and was also downregulated with age. PNUTS has emerged as a component of the DNA damage response that is recruited to the DNA damage sites and inhibits G2 arrest, interacts with telomere regulator TRF2,19 and confers a prosurvival effect. Interestingly, Boon et al7 reported downregulation of PNUTS gene and protein expression in aging hearts, suggesting a possible role in regulating the proapoptotic effects of miR-34a in cardiomyocytes. This hypothesis was confirmed by the finding that miR-34a directly regulates PNUTS expression. Furthermore, miR34a−/− mice show upregulation of PNUTS and pharmacological inhibition of miR-34a results in upregulation of PNUTS. PNUTS overexpression exhibits antiapoptotic effect in cardiomyocytes in response to H2O2-induced apoptosis in vitro. This finding was even further bolstered when in vivo overexpression of PNUTS showed preservation of cardiac contractile function after infarction, recapitulating what the authors had observed with the inhibition of miR-34a. The apoptotic response after ischemia is mediated by DNA damage that occurs as a consequence of oxidative stress,20 and it is possible that the prosurvival effect of blocking miR-34a or overexpressing PNUTS is derived from the reduced proapoptotic response, independent of p53,21 that has been shown to occur in cardiomyocytes.22

This exciting new study adds an important piece to the complex cardiac aging puzzle. These findings open a new therapeutic approach to limiting the detrimental effects of cardiomyocyte apoptosis after infarction. Transient therapeutic suppression of miR-34a or increasing PNUTS activity could be beneficial to cardiac remodeling and function. However, prolonged suppression of miR-34a could be risky because of a possible procancerous effect, thus limiting its use as a chronic antiaging therapy. There is much to be learned about cardiac aging, but as the world’s population ages, the importance of understanding the fundamental biology will become even more critical.

Disclosures

None.

Footnotes

  • The opinions expressed in this Commentary are not necessarily those of the editors or of the American Heart Association.

  • Commentaries serve as a forum in which experts highlight and discuss articles (published here and elsewhere) that the editors of Circulation Research feel are of particular significance to cardiovascular medicine.

  • Commentaries are edited by Aruni Bhatnagar.

  • © 2013 American Heart Association, Inc.

References

  1. 1.↵
    1. Ho AD,
    2. Wagner W,
    3. Mahlknecht U
    . Stem cells and ageing. The potential of stem cells to overcome age-related deteriorations of the body in regenerative medicine. EMBO Rep. 2005;6:S35–S38.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lakatta EG
    . Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev. 2002;7:29–49.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Wellenius GA,
    2. Mittleman MA
    . Disparities in myocardial infarction case fatality rates among the elderly: the 20-year Medicare experience. Am Heart J. 2008;156:483–490.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bergmann O,
    2. Bhardwaj RD,
    3. Bernard S,
    4. Zdunek S,
    5. Barnabé-Heider F,
    6. Walsh S,
    7. Zupicich J,
    8. Alkass K,
    9. Buchholz BA,
    10. Druid H,
    11. Jovinge S,
    12. Frisén J
    . Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98–102.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Senyo SE,
    2. Steinhauser ML,
    3. Pizzimenti CL,
    4. Yang VK,
    5. Cai L,
    6. Wang M,
    7. Wu TD,
    8. Guerquin-Kern JL,
    9. Lechene CP,
    10. Lee RT
    . Mammalian heart renewal by pre-existing cardiomyocytes. Nature. 2013;493:433–436.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Loffredo FS,
    2. Steinhauser ML,
    3. Jay SM,
    4. et al
    . Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153:828–839.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Boon RA,
    2. Iekushi K,
    3. Lechner S,
    4. et al
    . MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107–110.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ambros V
    . microRNAs: tiny regulators with great potential. Cell. 2001;107:823–826.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Griffiths-Jones S,
    2. Saini HK,
    3. van Dongen S,
    4. Enright AJ
    . miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36:D154–D158.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Lewis BP,
    2. Burge CB,
    3. Bartel DP
    . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Small EM,
    2. Olson EN
    . Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469:336–342.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Eulalio A,
    2. Mano M,
    3. Dal Ferro M,
    4. Zentilin L,
    5. Sinagra G,
    6. Zacchigna S,
    7. Giacca M
    . Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012;492:376–381.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Dimmeler S,
    2. Nicotera P
    . MicroRNAs in age-related diseases. EMBO Mol Med. 2013;5:180–190.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Hermeking H
    . p53 enters the microRNA world. Cancer Cell. 2007;12:414–418.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hermeking H
    . MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012;12:613–626.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Vogel H,
    2. Lim DS,
    3. Karsenty G,
    4. Finegold M,
    5. Hasty P
    . Deletion of Ku86 causes early onset of senescence in mice. Proc Natl Acad Sci USA. 1999;96:10770–10775.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Yamakuchi M,
    2. Ferlito M,
    3. Lowenstein CJ
    . miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 2008;105:13421–13426.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Potente M,
    2. Ghaeni L,
    3. Baldessari D,
    4. Mostoslavsky R,
    5. Rossig L,
    6. Dequiedt F,
    7. Haendeler J,
    8. Mione M,
    9. Dejana E,
    10. Alt FW,
    11. Zeiher AM,
    12. Dimmeler S
    . SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21:2644–2658.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Landsverk HB,
    2. Mora-Bermúdez F,
    3. Landsverk OJ,
    4. Hasvold G,
    5. Naderi S,
    6. Bakke O,
    7. Ellenberg J,
    8. Collas P,
    9. Syljuåsen RG,
    10. Küntziger T
    . The protein phosphatase 1 regulator PNUTS is a new component of the DNA damage response. EMBO Rep. 2010;11:868–875.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Shukla PC,
    2. Singh KK,
    3. Quan A,
    4. et al
    . BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun. 2011;2:593.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. De Leon G,
    2. Sherry TC,
    3. Krucher NA
    . Reduced expression of PNUTS leads to activation of Rb-phosphatase and caspase-mediated apoptosis. Cancer Biol Ther. 2008;7:833–841.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Bialik S,
    2. Geenen DL,
    3. Sasson IE,
    4. Cheng R,
    5. Horner JW,
    6. Evans SM,
    7. Lord EM,
    8. Koch CJ,
    9. Kitsis RN
    . Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest. 1997;100:1363–1372.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
July 5, 2013, Volume 113, Issue 2
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • MicroRNA-34a Regulates Cardiac Ageing and FunctionBoon et alNature. 2013;495:107–110.
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Keep PNUTS in Your Heart
    Francesco S. Loffredo, James R. Pancoast and Richard T. Lee
    Circulation Research. 2013;113:97-99, originally published July 5, 2013
    https://doi.org/10.1161/CIRCRESAHA.113.301933

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Keep PNUTS in Your Heart
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Keep PNUTS in Your Heart
    Francesco S. Loffredo, James R. Pancoast and Richard T. Lee
    Circulation Research. 2013;113:97-99, originally published July 5, 2013
    https://doi.org/10.1161/CIRCRESAHA.113.301933
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Gene Expression & Regulation
  • Basic, Translational, and Clinical Research
    • Contractile Function
    • Cell Signaling/Signal Transduction

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured